Reading a Medication Study: Population, Outcomes, and Limitations

Have an article or manuscript to review? Request a Review Quote.

Reading a medication study starts before the headline result. Who took part? What was compared? What outcome was measured, and over what period? Those details decide how far the conclusion can travel.

Imagine a draft saying, “This medicine protects the kidneys.” The reference may be relevant, yet the sentence still leaves an editor with work to do. Which patients? What counted as protection? Compared with what?

A strong medical article keeps those answers attached to the claim. Here is a practical reading sequence for writers, editors, and teams preparing medication-related content.

1. Write down the study question

Start with one sentence: the study compared this treatment with this alternative, in these people, to measure this outcome over this period.

If you cannot complete that sentence, pause before writing the conclusion. A medicine’s name and a favorable result are not enough to describe what was tested.

Note the design too. Was treatment assigned randomly, or did researchers observe existing care? The design affects which alternative explanations need attention. NHLBI’s assessment tools distinguish randomized trials from observational designs rather than treating every study as interchangeable.^[1]

2. Check who was actually studied

Read the eligibility criteria, baseline table, and participant flow. A disease label can cover people with different ages, disease severity, previous treatment, and accompanying conditions.

For a writer, the question is concrete: does the draft describe the people represented in the evidence, or quietly expand the finding to everyone with the condition?

Missing representation does not automatically prove a treatment cannot help another group. It changes what this particular study directly establishes. Cochrane identifies differences in populations and care settings as important when interpreting applicability.^[2]

3. Keep the treatment and comparison together

Check the dose, treatment schedule, comparator, and other care participants received. A comparison with placebo does not establish superiority over every available medicine. A treatment added to usual care should not become a claim about using it alone.

Ask what differs between groups besides the assigned intervention. Consider adherence, additional treatment, and how the analysis handled participants who stopped treatment. These questions help explain what the reported comparison means.^[1]

4. Read the outcome definition, not just its shorthand

“Kidney benefit,” “heart benefit,” and “improvement” may be convenient labels. They are not complete outcome definitions.

Look for the primary outcome, its measurement, and its timing. Identify whether it describes symptoms, function, survival, a laboratory measure, or a combination of events.

FDA distinguishes outcomes that directly assess clinical benefit from surrogate endpoints used in their place. A change in a marker should not silently become a claim about a different patient outcome.^[3]

For a composite outcome, identify its components and examine their individual results. A difference in the combined outcome does not mean every component changed by the same amount, or that each had a separately established benefit.

A worked example: what DAPA-CKD actually examined

The original DAPA-CKD report provides a useful exercise in keeping the claim attached to its study. This is an example of reading a published trial, not a treatment recommendation.

• Participants: 4,304 people with chronic kidney disease, with or without type 2 diabetes. Entry criteria included an estimated glomerular filtration rate of 25–75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200–5,000 mg/g.
• Comparison: dapagliflozin 10 mg daily versus placebo.
• Primary outcome: a composite covering a sustained decline in estimated filtration of at least 50%, end-stage kidney disease, or death from kidney or cardiovascular causes.

The trial reported a lower occurrence of the primary composite outcome with dapagliflozin.^[4]

An editor now has a better question than “Does this medicine protect kidneys?”: does the draft identify the relevant population and measured outcome? A defensible summary preserves those details instead of making a universal promise. Other populations, doses, and treatment comparisons need their own evidence.

That is a practical task for clinical content and manuscript review: checking whether the wording matches what the reference actually supports.

5. Read the size of the effect and its uncertainty

Record the outcome in each group, the follow-up period, the effect measure, and its confidence interval. Do not treat a hazard ratio, risk ratio, and absolute risk reduction as interchangeable.

Statistical significance alone does not describe how important a result is. Likewise, a result that does not cross a significance threshold is not automatic proof that the treatments are equivalent. Cochrane recommends interpreting estimates alongside their uncertainty.^[2]

The absolute and relative risk guide explains why the same relative reduction can describe different absolute changes.

6. Ask what could change the interpretation

Review missing data, withdrawals, outcome measurement, treatment changes, and the analysis population. Ask how each issue could affect the answer, rather than counting limitations as though every item carried equal weight.^[1]

Read the harms alongside benefits. Check the protocol or registration when assessing whether an outcome was planned. CONSORT 2025 provides reporting guidance for randomized trials, including information that helps readers inspect the study.^[5]

Clear reporting makes assessment possible; it does not certify that a trial has no weaknesses. When an important detail is unavailable, name the gap instead of filling it with an assumption.

Before publishing, test your sentence against the source

Return to the sentence you want readers to remember. Does it preserve the population, comparison, outcome, timeframe, and important uncertainty? Does the reference support that sentence, rather than merely discuss the same topic?

The claim-to-reference guide provides another way to check that connection. If the question needs evidence beyond one paper, the targeted literature research guide explains how to define a useful search.

A concise sentence can still be precise. The work is deciding which details the reader needs—not removing every qualification until the claim sounds certain.

Frequently asked questions

References

1. NHLBI. Study Quality Assessment Tools.
2. Cochrane Handbook. Chapter 15: Interpreting results and drawing conclusions.
3. FDA. Surrogate Endpoint Resources for Drug and Biologic Development.
4. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816.
5. Hopewell S, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;388:e081123.